QNCX · As filed with the SEC
Quince Therapeutics cash flow statement, by fiscal year
The statement as Quince Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF CASH FLOWS · USD thousands
| USD thousands | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Cash flows from operating activities | ||||
| Net Loss | — | (56,828) | (31,385) | (51,660) |
| Net Loss | (83,979,000) | — | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Non-cash rent expense | — | — | 0 | (29,000) |
| Stock based compensation | 5,105,000 | 4,746,000 | 5,220,000 | 16,618,000 |
| Depreciation and amortization | 142,000 | 186,000 | 322,000 | 204,000 |
| Impairment loss on operating lease | — | 0 | 66 | 136 |
| Gain on sale of legacy assets | — | 0 | (78) | — |
| Loss on disposal of fixed assets | — | 0 | 37 | 94 |
| Change in the fair value of contingent consideration liabilities | 7,639,000 | 3,985,000 | 1,578,000 | — |
| Change in fair value of debt, net | 1,809,000 | 1,709,000 | 338,000 | — |
| Non-cash goodwill impairment charge | — | — | 0 | 825,000 |
| Non-cash intangible impairment charge | — | — | 5,900,000 | — |
| Change in fair value of warrants | 21,470,000 | — | — | — |
| Non-cash goodwill impairment charge | 0 | 17,130,000 | — | — |
| Reclassification of cumulative translation adjustment to net income | (477,000) | — | — | — |
| Amortization of discount on available-for-sale investments | (1,014,000) | (2,348,000) | (2,019,000) | (113,000) |
| Change in deferred tax liabilities due to acquisition of Novosteo, Inc. | — | 0 | (248) | (284) |
| Change in deferred tax liabilities | (4,963,000) | — | — | — |
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses and other current assets | 2,957,000 | (1,711,000) | 4,246,000 | 2,580,000 |
| Right of use assets, operating leases and operating lease liabilities | 104,000 | (135,000) | — | — |
| Other assets | 4,204,000 | (741,000) | (9,000) | 194,000 |
| Accounts payable | (940,000) | 927,000 | (288,000) | (5,943,000) |
| Accrued expenses and other current liabilities | 5,776,000 | 1,176,000 | (1,972,000) | (6,660,000) |
| Other liabilities | 742,000 | — | — | — |
| Net cash used in operating activities | (41,425,000) | (31,904,000) | (18,292,000) | (44,038,000) |
| Cash flow from investing activities: | ||||
| Purchase of investments | — | — | (113,781,000) | (75,021,000) |
| Proceeds from maturities of investments | — | — | 111,209,000 | 82,493,000 |
| Cash acquired from Novosteo, Inc. | — | — | 0 | 10,593,000 |
| Purchase of investments | (34,418,000) | (89,562,000) | — | — |
| Proceeds from maturities of investments | 57,997,000 | 111,727,000 | — | — |
| Advancement of note receivable | — | 0 | (1,000) | — |
| Cash paid in acquisition of EryDel S.p.A. net of cash acquired | — | 0 | (2,116) | — |
| Proceeds from disposal of assets | — | 0 | 90 | 70 |
| Purchase of property and equipment | (352,000) | (257,000) | (160,000) | (133,000) |
| Net cash provided by investing activities | 23,227,000 | 21,908,000 | (5,758,000) | 18,002,000 |
| Cash flows from financing activities: | ||||
| Payment of contingent consideration | 0 | (5,000,000) | — | — |
| Proceeds from issuance of common stock, common warrants, and pre-funded warrants pursuant to private placement offering, net of issuance costs | 11,426,000 | — | — | — |
| Proceeds from issuance of common stock upon public offering, net of issuance costs | 6,263,000 | — | — | — |
| Proceeds from issuance of common stock upon exercise of stock options | 220,000 | 225,000 | 149,000 | 148,000 |
| Proceeds from issuance of common stock in connection with open market sales agreement, net of issuance costs | — | — | 0 | 608,000 |
| Proceeds from private placement offering, net of issuance costs | — | — | — | 0 |
| Payments of finance leases | — | 0 | (6) | (49) |
| Net cash provided by (used in) financing activities | 17,909,000 | (4,775,000) | 143,000 | 707,000 |
| Effect of exchange rate changes on cash | (114,000) | 231,000 | 80,000 | 184,000 |
| Net decrease in cash and cash equivalents | (403,000) | (14,540,000) | (23,827,000) | (25,145,000) |
| Cash and cash equivalents at beginning of period | 6,212,000 | 20,752,000 | 44,579,000 | 69,724,000 |
| Cash and cash equivalents at end of period | 5,809,000 | 6,212,000 | 20,752,000 | 44,579,000 |
| Supplemental disclosures of non-cash information: | ||||
| Net assets acquired of EryDel S.p.A. in exchange for common stock | — | — | — | 16,503 |
| Ery Del | — | 0 | 63,732 | — |
| Novosteo | — | — | 0 | — |
| Right-of-use assets obtained in exchange for new operating lease liabilities | — | — | 0 | 411,000 |
| Right-of-use asset and financing lease liability reduction as a result of lease modification | — | — | (70,000) | — |
| Right-of-use asset and operating lease liability reduction as a result of lease modification | — | — | 0 | (640,000) |
| Interest payment on debt | 234,000 | — | — | — |
| Right-of-use assets obtained in exchange for new operating lease liabilities | 0 | 216,000 | — | — |
| Right-of-use asset and financing lease liability reduction as a result of lease modification | — | 0 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.